General Surgery Department of Zhongnan Hospital, Wuhan University, 169 Donghu Road, Wuchang, Wuhan, Hubei, 430071, China,
Inflammation. 2013 Dec;36(6):1348-56. doi: 10.1007/s10753-013-9674-3.
In the present study, we investigated the protective effects of sivelestat on acute pancreatitis (AP) in a rat model. Sivelestat is a specific neutrophil elastase inhibitor, which has been developed in Japan in 1991. Varying doses of sivelestat in normal saline were infused continuously in sivelestat-treated groups through osmotic pumps. Blood and pancreas samples were collected for serological and histopathological studies, and ten rats in each group were taken for survival observation. Increasing doses of sivelestat inhibits the expression of lipase, amylase, corticosterone, IL-1β, TNF-α, and nuclear factor-κB. Furthermore, sivelestat reduces the inflammatory cells infiltration, histological damage, and mortality rate. Meanwhile, the total antioxidant power and serum level of IL-4 in high-dose sivelestat-treated groups were increased. Our findings suggest that the increasing doses of sivelestat protect against caerulein-induced AP in rats, and this protection is possibly associated with the anti-inflammatory ability of sivelestat.
在本研究中，我们在大鼠模型中研究了西维来司他对急性胰腺炎（AP）的保护作用。西维来司他是一种特异性中性粒细胞弹性蛋白酶抑制剂，于 1991 年在日本开发。通过渗透泵持续向西维来司他治疗组的生理盐水输注不同剂量的西维来司他。采集血液和胰腺样本进行血清学和组织病理学研究，每组 10 只大鼠用于生存观察。增加剂量的西维来司他抑制脂肪酶、淀粉酶、皮质酮、IL-1β、TNF-α 和核因子-κB 的表达。此外，西维来司他减少炎症细胞浸润、组织损伤和死亡率。同时，高剂量西维来司他治疗组的总抗氧化能力和血清 IL-4 水平增加。我们的研究结果表明，增加剂量的西维来司他可预防大鼠的雨蛙肽诱导的 AP，这种保护可能与西维来司他的抗炎能力有关。
